FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial
Kuo PH, Carlson KR, Christensen I, Girardi M, Heald PW. FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. Molecular Imaging And Biology 2008, 10: 306-314. PMID: 18665425, DOI: 10.1007/s11307-008-0161-4.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaFDG PET/CTPhase II trialParticular positron emission tomographyT-cell lymphomaII trialNodal diseaseInitial PET/CT scanPET/CT scansEarly clinical trialsEvaluation of responseHistone deacetylase inhibitorsAlters gene transcriptionPositron emission tomographyFDG uptakeCutaneous lesionsFDG-PETPrognostic valueFuture trialsClinical trialsConclusionFurther studiesCell lymphomaCT scanDeacetylase inhibitorsHDAC inhibitorsFDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma
Kuo PH, McClennan BL, Carlson K, Wilson LD, Edelson RL, Heald PW, Girardi M. FDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma. Molecular Imaging And Biology 2008, 10: 74-81. PMID: 18196347, DOI: 10.1007/s11307-007-0127-y.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaPET/CTT-cell lymphomaFDG uptakeD-glucose positron emission tomography/FDG PET/CTPositron emission tomography/PET/CT scansComprehensive case seriesTomography (CT) of patientsMonitoring of responseMalignant adenopathyActive diseaseAdvanced diseaseCutaneous examinationVisceral diseaseVisceral involvementLymph nodesCase seriesCutaneous lesionsPhysical examinationThicker tumorsTomography/Physical examIndividual patients